Core Viewpoint - The company, Nanning Baling Technology Co., Ltd., has approved the grant of reserved stock options to the incentive objects under the first stock option incentive plan during its board meetings held on August 11, 2025 [1][6]. Group 1: Announcement Details - The company held the eighth meeting of the seventh board's remuneration and assessment committee and the twenty-first meeting of the seventh board to review the proposal for granting reserved stock options [1]. - The details of the stock option incentive plan were disclosed on August 12, 2025, through various financial news outlets and the company's official website [2]. Group 2: Public Disclosure and Review - The company publicly disclosed the list of reserved stock option incentive objects from August 12 to August 21, 2025, for a period of 10 days [2]. - No objections were raised by employees regarding the list of reserved stock option incentive objects during the public disclosure period [3]. Group 3: Verification Opinions - The remuneration and assessment committee verified that all individuals listed as incentive objects are company directors, middle management, and core technical (business) personnel, excluding independent directors and major shareholders [4]. - The committee confirmed that the listed incentive objects do not fall under any disqualifying conditions as per the relevant regulations [4][5]. - The basic information regarding the incentive objects is accurate, with no falsehoods or significant omissions [5].

Core Viewpoint - The legal opinion letter confirms that the conditions for the second exercise period of the stock option incentive plan for Zhaoyi Innovation Technology Group Co., Ltd. have been met, allowing eligible participants to exercise their stock options [2][10]. Group 1: Conditions for Stock Option Exercise - The stock options can only be exercised if certain conditions are met, including no negative audit opinions on financial reports for the last fiscal year and compliance with legal and regulatory requirements [3][4]. - The performance target for the second exercise period is set at a revenue growth rate of no less than 120% compared to the average revenue from 2018 to 2020, which was approximately 331.52 million yuan [9]. Group 2: Achievement of Exercise Conditions - The company has not encountered any disqualifying events in the last 12 months, such as being deemed inappropriate by the stock exchange or the China Securities Regulatory Commission (CSRC) [6]. - A total of 904 individuals are eligible to exercise their options, with the total number of exercisable stock options amounting to approximately 2.34 million shares, representing 24.90% of the granted options [10]. Group 3: Approval and Authorization - The board of directors has been authorized by the shareholders to handle matters related to the stock option incentive plan, including determining the grant date and processing necessary approvals [10]. - The legal opinion confirms that the conditions for the second exercise period have been achieved and that the necessary approvals and authorizations are in place, complying with relevant regulations and the company's articles of association [10].

Group 1 - The company held the 13th meeting of the 6th Board of Directors and the 12th meeting of the 6th Supervisory Board on August 14, 2025, where it approved the proposal to cancel part of the stock options from the 2024 stock option incentive plan [1][2] - A total of 418,000 stock options will be canceled, which includes options from 5 individuals who left the company for personal reasons and 3 individuals whose performance indicators were either qualified or unqualified [1][2] - The company has submitted the cancellation application to the Shenzhen branch of China Securities Depository and Clearing Co., Ltd., and the cancellation has been confirmed and completed as of the announcement date [1] Group 2 - The cancellation of stock options complies with the relevant laws and regulations, including the "Management Measures for Equity Incentives of Listed Companies" and the company's "2024 Stock Option Incentive Plan (Draft)" [2] - The cancellation will not affect the company's share capital structure and does not harm the interests of the company or other shareholders, particularly minority shareholders [2]

Core Viewpoint - The report discusses the stock option incentive plan of Beijing Wandong Medical Technology Co., Ltd. for 2025, detailing the approval process and compliance with relevant regulations [1][2][3]. Summary by Sections 1. Definition and Terms - The report defines key terms related to the stock option incentive plan, including "incentive objects," "grant date," "exercise price," and "exercise conditions" [1]. 2. Approval Process - The company held multiple meetings to approve the stock option incentive plan, including the sixth meeting of the tenth board of directors on March 20, 2025, and the sixth meeting of the tenth supervisory board on the same day [4][5]. - The plan was publicly disclosed from March 28 to April 8, 2025, with no objections raised by employees [4]. - The annual shareholders' meeting on April 16, 2025, approved the plan and authorized the board to handle related matters [4]. 3. Compliance and Conditions - The independent financial advisor confirmed that the incentive plan met all necessary conditions and approvals as per the regulations [6][8]. - The report outlines that the company and the incentive objects have not encountered any disqualifying circumstances as per the management regulations [7]. 4. Granting Details - A total of 120 stock options were granted to 14 core personnel, representing 11.11% of the total options planned for issuance [8]. - The total number of stock options involved in the incentive plan does not exceed 1% of the company's total equity [8]. 5. Financial Impact - The independent financial advisor recommends that the company account for the expenses related to the stock option plan in accordance with relevant accounting standards, noting potential dilution effects [8]. 6. Conclusion - The independent financial advisor concludes that the stock option incentive plan has obtained the necessary approvals and complies with all relevant laws and regulations, ensuring no harm to the company or its shareholders [9].

Core Viewpoint - The company has announced the granting of reserved stock options under its 2025 stock option incentive plan, with a total of 1.2 million options to be granted at an exercise price of 15.05 yuan per option, effective from August 22, 2025 [1][10]. Group 1: Incentive Plan Details - The reserved grant date is set for August 22, 2025, with a total of 1.2 million options to be granted [1]. - The exercise price for the stock options is established at 15.05 yuan per option [1]. - The incentive plan has undergone necessary approval procedures and disclosures, including resolutions from the board and supervisory committee [2][3]. Group 2: Approval and Compliance - The 2025 stock option incentive plan has been approved by the company's 2024 annual general meeting, granting the board the authority to manage related matters [3]. - The supervisory committee has verified the list of incentive recipients and found no objections from employees during the public notice period [2][8]. - The board has confirmed that both the company and the incentive recipients meet the conditions for granting stock options as per relevant regulations [4][11]. Group 3: Performance Assessment - The stock options will have a validity period of up to 60 months from the grant date, with specific waiting and exercise periods defined [5][6]. - The performance assessment for the stock options will be based on the company's revenue growth and R&D investment rates over the years 2025 to 2027 [6][7]. - Individual performance assessments will also be conducted, determining the exercise ratio based on internal performance evaluation [6][7]. Group 4: Financial Impact - The company will use the Black-Scholes model to determine the fair value of the stock options at the grant date, impacting the company's financial statements [9][10]. - The estimated costs associated with the stock option plan will be amortized over the relevant periods, with a minor expected impact on the company's operating performance [10][11].

Core Viewpoint - The company has reviewed and approved the list of candidates for the 2025 stock option incentive plan, confirming compliance with relevant laws and regulations [1][2][3] Group 1: Incentive Plan Overview - The content of the incentive plan is consistent with what was approved at the 2024 annual shareholders' meeting [1] - The candidates for the incentive plan include current directors, senior management, core management, and key technical/business personnel, excluding independent directors, supervisors, and major shareholders [1][2] Group 2: Eligibility Criteria - All individuals included in the incentive plan meet the qualifications set forth by the Company Law, Securities Law, and the company's articles of association [2] - There are no disqualifying conditions as outlined in the management regulations, such as being deemed inappropriate by the stock exchange or the China Securities Regulatory Commission [2] Group 3: Granting Conditions - The conditions for granting the stock options have been met, and the designated grant date of August 22, 2025, is in accordance with the management regulations [3] - The board has approved the grant of 1.2 million stock options to 14 eligible candidates at an exercise price of 15.05 yuan per option [3]

兆易创新科技集团股份有限公司 第五届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 兆易创新科技集团股份有限公司（以下简称"公司"）第五届董事会第五次 会议的会议通知和材料已于 2025 年 8 月 12 日以电子邮件方式发出，会议于 2025 年 8 月 22 日以现场结合通讯方式召开。本次会议由董事长朱一明先生主持，会 议应出席董事 9 名，实际出席董事 9 名；公司部分高级管理人员列席了本次会议。 本次会议的召集和召开程序符合《中华人民共和国公司法》等有关法律、行政法 规、部门规章、规范性文件和《公司章程》的有关规定。 经与会董事认真审议，以记名投票表决方式一致通过以下议案： 一、关于审议公司《2025 年半年度报告》及其摘要的议案 本议案具体内容请详见同日刊登在《证券时报》及上海证券交易所网站 （http://www.sse.com.cn）上的《兆易创新 2025 年半年度报告》及其摘要。 本议案已经公司董事会审计委员会审议通过。 表决结果：9 票同意、0 票反对、0 票弃权。 二、关于审议《 ...

Core Viewpoint - The company has approved the list of candidates for the first phase of the stock option incentive plan, ensuring compliance with relevant regulations and confirming that no objections were raised during the public disclosure period [1][2]. Disclosure Situation - The company publicly disclosed the list of candidates for the stock option incentive plan on August 12, 2025, with a public notice period from August 12 to August 21, 2025, lasting 10 days [2]. - No objections were received from employees regarding the list of candidates during the public disclosure period [2]. Verification Opinions - The candidates included in the incentive plan are all directors, middle management, and core technical (business) personnel of the company and its subsidiaries, excluding independent directors and major shareholders [3][4]. - The verification confirmed that none of the candidates fall under the disqualifying conditions outlined in the relevant regulations, such as being deemed inappropriate by the stock exchange or regulatory authorities within the last 12 months [3]. - The basic information of the candidates is accurate, with no falsehoods or significant omissions identified [4].

恒生电子股份有限公司 恒生电子股份有限公司 董事会薪酬与考核委员会关于 2025 年员工持股计划和 一、关于2025年员工持股计划的核查意见 根据《公司法》、《上市公司实施员工持股计划试点的指导意见》、《上 海证券交易所上市公司自律监管指引第1号——规范运作》等有关法律法规 及公司《章程》的规定，恒生电子股份有限公司（以下简称"公司"）董事 会薪酬与考核委员会就公司2025年员工持股计划（以下简称"本次员工持股 计划"）事项进行了认真核查和了解，并对该事项发表如下审核意见： （以 下简称"指导意见"）等法律、法规规定的禁止实施员工持股计划的情形； 公司编制《恒生电子股份有限公司2025年员工持股计划草案》及其摘要的程 序合法、有效。员工持股计划内容符合《指导意见》等有关法律、法规及规 范性文件的规定；公司审议本次员工持股计划相关议案的程序和决策合法、 有效，不存在损害公司及全体股东利益的情形，亦不存在摊派、强行分配等 方式强制公司员工参与本员工持股计划的情形，不存在公司向员工持股计划 持有人提供贷款、贷款担保或任何其他财务资助的计划或安排。 法律、法规和规范性文件规定的持有人条件，符合员工持股计划规定的持有 ...

上海复星医药（集团）股份有限公司 董事会薪酬与考核委员会 一、本公司具备实施 2025 年 A 股期权计划的主体资格，不存在《管理办法》 等规定的禁止实施股权激励计划的如下情形： 示意见的审计报告； 关于 2025 年 A 股股票期权激励计划相关事项的核查意见 上海复星医药（集团）股份有限公司（以下简称"本公司"）董事会薪酬与 考核委员会依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》 （以下简称"《证券法》"）、 《上市公司股权激励管理办法》 （以下简称"《管理办法》"）等相关法律法规及规范性文件和《上海复星医药 （集团）股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，对《上 海复星医药（集团）股份有限公司 2025 年 A 股股票期权激励计划（草案）》（以 下简称"2025 年 A 股期权计划" ）及相关资料进行核查核实后，发表如下核查意 见： 《管理办法》以及《公司章程》等 规定；对各激励对象股票期权的授予安排及行权安排（包括但不限于授予数量、 授予日期、授予条件、行权价格、等待期、行权期、行权条件等）未违反有关法 律法规的规定，未损害本公司及全体股东的利益 ...